|The VEGF-B167 vegfb (Catalog #MBS691097) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Rabbit Anti-Human VEGF-B167 reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s VEGF-B167 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB).
Western Blot: Use at 2-5 ug/ml. Researchers should empirically determine the suitability of the VEGF-B167 vegfb for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The VEGF-B167 vegfb product has the following accession number(s) (GI #344179103) (NCBI Accession #NP_003368.1) (Uniprot Accession #P49765). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity. Five mammalian members, including VEGF-A, B, C, D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is coexpressed and can heterodimerize with VEGF. By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist. The two VEGF-B isoforms have identical amino-terminal cysteine knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGFR-1), but not VEGFR-2 or VEGFR-3. On endothelial cells, ligation of VEGFR-1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin1 (NP1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance. Besides VEGF-B, NP1 has been shown to bind PlGF-2, VEGF165 and VEGFR-1. The many interactions of NP1 with VEGF ligands and receptor suggest that NP1 may function as a regulator of angiogenesis.
Immunogen: Recombinant human VEGF-B167
Preparation: Produced from sera of rabbits pre-immunized with highly pure (>95%) recombinant human VEGF-B167 (Ala21-Arg188) produced in E. coli. Buffer: PBS. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing VEGF-B167 are readily searchable from our website. Different antibodies against the same target such as VEGF-B167 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.